Jerome Tannenbaum

KaZee Board Member

Dr. Tannenbaum holds an M.D. from Vanderbilt University School of Medicine and a Ph.D. in Pharmacology from Vanderbilt University School of Graduate Studies. He completed his training in Internal Medicine at the Jewish Hospital of St. Louis and his Nephrology training at Barnes Hospital, both affiliates of Washington University of St. Louis School of Medicine. He is Board Certified in Internal Medicine and Nephrology and is a Fellow of the American College of Physicians (FACP). Dr. Tannenbaum is a licensed physician in the State of Tennessee.

He was the founder of REN Corporation-USA (formerly NASDAQ: RENL), a publicly traded provider of dialysis services, where he served as President, Chairman and Chief Executive Officer from 1987 to 1993.

In 1993, he founded Medical Information Management Systems, Inc. (MIMS), a medical software company and developer of the robust Pearl® EMR system. Pearl® was the first Internet-capable Electronic Medical Record and an early pioneer in Community Health Information Networking. It is the core of one of the largest telemedicine programs to date. Pearl® provides real-time transaction based Electronic Medical Records through wide area networks to dialysis centers, large multi-specialty practice groups, and prison health networks in over 25 states. In addition to transaction-based EMR functions, the Pearl® system operates from a highly normalized relational database which is capable of analyzing episodes of care and population based statistics with respect to clinical and financial data.

In 1998, Dr. Tannenbaum became Chairman and Chief Executive Officer of National Nephrology Associates, Inc. (NNA), a nationwide dialysis services provider that he co-founded with some of his original management team from REN. The company was sold to Renal Care Group, a NYSE company. Dr. Tannenbaum left NNA in June 2003 to co-found Diversified Specialty Institutes, Inc. (DSI) with Dr. G. Patrick Maxwell, and certain former members of the NNA, MIMS, and REN management teams. DSI established a comprehensive women’s center in Philadelphia, Pennsylvania which focused on the treatment of patients with breast cancer.

In 2005, Dr. Tannenbaum led the formation and expansion of DSI Renal, Inc. (an affiliate of DSI), a company that operated over 110 dialysis centers across 26 states, and served as its Chairman and Chief Executive Officer, which at the time of its purchase by DaVita (NYSE:DVA), was the 4th largest dialysis company in the United States. DSI made use of the Pearl® system for conducting multi-center clinical trials that included the evaluation of bio-impedance monitoring of fluid status with bio-impedance, and the use of transcutaneous oximetry (TcO2) for improving the early detection of peripheral vascular disease in patients on dialysis. DSI also conducted early trials in the use of home patient monitoring of patients on dialysis to determine whether inter-dialytic monitoring could reduce mortality and morbidity. All trials were presented and approved by an IRB prior to initiation.

In late 2008, Dr. Tannenbaum left DSI Renal to found Sanderling Healthcare, LLC, and to bring specialty medical care to rural communities through the use of telemedicine. Sanderling has established one of the first renal telemedicine programs in the United States and is currently establishing tele-nephrology at multiple rural communities in the United States through affiliations with the local primary care physicians and hospitals. Sanderling plans to include additional internal medicine subspecialties, e.g. cardiology, infectious disease, and pulmonary medicine to its telemedicine practice over time.